feed,title,long_url,short_url
MedRxiv,"Immunogenicity and durability against Omicron BA.1, BA.2 and BA.4/5 variants at 3 to 4 months after a heterologous COVID-19 booster vaccine in healthy adults with a two-doses CoronaVac vaccination",https://medrxiv.org/cgi/content/short/2022.11.24.22282735v1?rss=1,https://bit.ly/3F6Yua0
MedRxiv,Heterogeneity of treatment effect of higher dose dexamethasone by geographic region in patients with COVID-19 and severe hypoxemia - A post hoc evaluation of the COVID STEROID 2 trial,https://medrxiv.org/cgi/content/short/2022.11.23.22282463v1?rss=1,https://bit.ly/3F6Yuqw
MedRxiv,Population Pharmacokinetics and Exposure-Response Analysis of Sotrovimab in the Early Treatment of COVID-19,https://medrxiv.org/cgi/content/short/2022.11.23.22282478v1?rss=1,https://bit.ly/3id094Z
MedRxiv,Community incidence patterns drive the risk of SARS-CoV-2 outbreaks and alter intervention impacts in a high-risk institutional setting,https://medrxiv.org/cgi/content/short/2022.11.22.22282480v1?rss=1,https://bit.ly/3F6Yve4
MedRxiv,Global Expansion of SARS-CoV-2 Variants of Concern: Dispersal Patterns and Influence of Air Travel,https://medrxiv.org/cgi/content/short/2022.11.22.22282629v1?rss=1,https://bit.ly/3VsDUqF
MedRxiv,Transmission prevention behaviors in US households with SARS-CoV-2 cases in 2020,https://medrxiv.org/cgi/content/short/2022.11.25.22282730v1?rss=1,https://bit.ly/3Vib8J1
MedRxiv,Prolonged T-cell activation and long COVID symptoms independently associate with severe disease at 3 months in a UK cohort of hospitalized COVID-19 patients,https://medrxiv.org/cgi/content/short/2022.11.25.22282759v1?rss=1,https://bit.ly/3F6YvL6
